En desarrollo
Salud·13/6/2026Resumen IA
Life Biosciences' Experimental Treatment ER-100 Administered to First Patient in Phase 1 Trial
Life Biosciences has administered its experimental treatment ER-100, targeting age-related vision loss diseases like glaucoma and NAION, to the first participant in a Phase 1 clinical trial. The treatment aims to restore cellular gene expression patterns to a younger state. The primary focus of this early-stage trial is to assess the safety and tolerability of ER-100 in humans.
H
Hürriyet Teknoloji2 min de lectura
